Amylyx Pharmaceuticals, Inc.

NasdaqGS:AMLX Stock Report

Market Cap: US$257.4m

Amylyx Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:AMLX Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
02 Dec 24SellUS$30,007Camille BedrosianIndividual5,421US$5.54
30 Sep 24SellUS$27,840Gina MazzarielloIndividual8,709US$3.20
30 Sep 24SellUS$59,414Joshua CohenIndividual18,589US$3.20
30 Sep 24SellUS$59,429Justin KleeIndividual18,589US$3.20
30 Sep 24SellUS$36,559Camille BedrosianIndividual11,442US$3.20
12 Sep 24BuyUS$101,368James FratesIndividual40,000US$2.53
05 Sep 24BuyUS$106,590Karen FirestoneIndividual50,000US$2.13
03 Sep 24BuyUS$219,800George MilneIndividual100,000US$2.20
15 May 24BuyUS$9,436Daphne QuimiIndividual5,000US$1.89
05 Mar 24SellUS$33,560James FratesIndividual1,792US$18.73
05 Mar 24SellUS$28,841Gina MazzarielloIndividual1,540US$18.73
05 Mar 24SellUS$77,440Justin KleeIndividual4,135US$18.73
05 Mar 24SellUS$77,440Joshua CohenIndividual4,135US$18.73
23 Feb 24SellUS$53,231Gina MazzarielloIndividual2,838US$18.76
09 Jan 24SellUS$45,915Patrick YeramianIndividual2,812US$16.33
09 Jan 24SellUS$95,372Joshua CohenIndividual5,841US$16.33
09 Jan 24SellUS$44,347James FratesIndividual2,716US$16.33
09 Jan 24SellUS$95,372Justin KleeIndividual5,841US$16.33

Insider Trading Volume

Insider Buying: AMLX insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of AMLX?
Owner TypeNumber of SharesOwnership Percentage
General Public2,780,2824.08%
Individual Insiders6,957,47610.2%
VC/PE Firms19,197,83328.2%
Institutions39,146,87757.5%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 78.86% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
8.66%
ALS Investment Fund
5,895,280US$22.3m0%no data
6.82%
TCG Crossover Management, LLC
4,643,812US$17.6m0%1.66%
6.55%
Perceptive Advisors LLC
4,458,741US$16.9m110%0.41%
6.17%
Panacea Venture Management Co., Ltd.
4,200,000US$15.9m0%31.15%
4.54%
The Vanguard Group, Inc.
3,089,645US$11.7m-26.9%no data
4.26%
Joshua Cohen
2,898,403US$11.0m2.73%no data
4.2%
Justin Klee
2,862,093US$10.8m2.28%no data
3.74%
BlackRock, Inc.
2,548,206US$9.6m-4.55%no data
3.4%
The Morningside Group Limited
2,313,227US$8.7m0%1.7%
2.97%
Alyeska Investment Group, L.P.
2,023,420US$7.6m11%0.04%
2.94%
683 Capital Management, LLC
2,000,000US$7.6m33.2%0.81%
2.92%
Almitas Capital LLC
1,988,563US$7.5m4.45%1.82%
2.9%
abrdn plc
1,972,242US$7.5m1,570%0.01%
2.79%
Citadel Advisors LLC
1,899,560US$7.2m41.3%0.01%
2.6%
Acadian Asset Management LLC
1,770,197US$6.7m46.1%0.02%
2.06%
Nantahala Capital Management, LLC
1,404,564US$5.3m0%0.41%
2.03%
Goldman Sachs Asset Management, L.P.
1,385,420US$5.2m3.64%no data
1.69%
Farallon Capital Management, L.L.C.
1,150,221US$4.3m0%0.03%
1.29%
Connor, Clark & Lunn Investment Management Ltd.
880,745US$3.3m41.6%0.02%
1.26%
George Milne
858,571US$3.2m22.1%no data
1.13%
Bank of America Corporation, Asset Management Arm
768,901US$2.9m119%no data
1.02%
D. E. Shaw & Co., L.P.
691,066US$2.6m-47.2%no data
0.98%
Walleye Capital LLC
670,594US$2.5m987%0.02%
0.98%
Alpha Wave Global, LP
669,487US$2.5m0%0.35%
0.95%
AQR Capital Management, LLC
649,079US$2.5m-80.5%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 11:55
End of Day Share Price 2025/01/02 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Amylyx Pharmaceuticals, Inc. is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joel BeattyBaird
Geoffrey MeachamBofA Global Research
Charlie YangBofA Global Research